BRIEF published on 06/16/2026 at 19:48, 3 months 28 days ago Valerio Therapeutics Appoints New CEO and Confirms AGM Resolutions Biotechnology CEO Transition Valerio Therapeutics Gilles Besin RNA Medicines
PRESS RELEASE published on 06/16/2026 at 19:43, 3 months 28 days ago Informations privilégiées / Autres communiqués Valerio Therapeutics nomme Gilles Besin au poste de Directeur Général et annonce les résultats de son Assemblée Générale Annuelle, marquant une nouvelle phase d'innovation dans les thérapies ciblées de précision Biotechnologie Assemblée Générale Directeur Général Valerio Therapeutics Gilles Besin
PRESS RELEASE published on 06/16/2026 at 19:43, 3 months 28 days ago Inside Information / Other news releases Valerio Therapeutics appoints Gilles Besin as CEO, approved all resolutions at annual general meeting. Besin brings deep RNA and targeted delivery expertise to drive innovation Annual General Meeting Valerio Therapeutics Gilles Besin RNA Medicines Targeted Delivery
BRIEF published on 12/17/2025 at 11:02, 9 months 29 days ago Valerio Therapeutics Welcomes Professor Eric Vivier to its Board of Directors Board Of Directors Oncology Immunology Valerio Therapeutics Eric Vivier
BRIEF published on 12/17/2025 at 11:02, 9 months 29 days ago Valerio Therapeutics Appoints Professor Eric Vivier as Board Observer Board Of Directors Immunology Valerio Therapeutics Professor Eric Vivier Oncology Strategy
BRIEF published on 12/17/2025 at 11:02, 9 months 29 days ago Valerio Therapeutics nomme le professeur Eric Vivier observateur au conseil d'administration Conseil D'administration Valerio Thérapeutique Immunologie Professeur Eric Vivier Stratégie En Oncologie
BRIEF published on 12/17/2025 at 11:02, 9 months 29 days ago Valerio Therapeutics Accueille le Professeur Eric Vivier au Conseil d'Administration Conseil D'administration Oncologie Valerio Therapeutics Immunologie Eric Vivier
PRESS RELEASE published on 12/17/2025 at 10:57, 9 months 29 days ago Inside Information / Other news releases Valerio Therapeutics appoints Prof. Eric Vivier as Observer to Board of Directors. Prof. Vivier, a renowned immunologist, will bring over 30 years of experience to drive innovative tumor treatment approaches Board Of Directors Valerio Therapeutics Professor Eric Vivier Immunologist Tumor Treatment
PRESS RELEASE published on 12/17/2025 at 10:57, 9 months 29 days ago Informations privilégiées / Autres communiqués Valerio Therapeutics annonce la désignation du Professeur Eric Vivier en qualité d'Observateur de son Conseil d’Administration. Le Professeur apportera son expertise en immunologie pour développer des traitements innovants en oncologie Conseil D'administration Valerio Therapeutics Immunologie Professeur Eric Vivier Observateur
PRESS RELEASE published on 10/30/2025 at 09:05, 11 months 16 days ago Half-Year Financial Report 2025
Published on 10/15/2026 at 16:10, 2 hours 35 minutes ago North Shore Announces Extension to Falcon Property Option Agreement and Resource Stock Digest Engagement
Published on 10/15/2026 at 15:15, 3 hours 30 minutes ago Gold Terra to Host Community Town Hall Meeting in Yellowknife on October 21, 2026
Published on 10/15/2026 at 14:31, 4 hours 14 minutes ago First Breach to Present at the 20th Annual LD Micro Main Event
Published on 10/15/2026 at 14:05, 4 hours 40 minutes ago Innodata to Report Third Quarter 2026 Results
Published on 10/15/2026 at 14:00, 4 hours 45 minutes ago Tectonic Metals Drills 2.41 g/t Au over 59.44 metres, Including 11.82 g/t Au over 10.67 metres and 39.96 g/t Au over 3.05 metres at Alpha Bowl, Flat Gold Project, Alaska
Published on 10/15/2026 at 18:03, 42 minutes ago AIXTRON Q3 2026: Order intake and operating profitability significantly exceed market expectations
Published on 10/15/2026 at 18:00, 45 minutes ago BOA Concept Group étoffe son offre et intègre les AMR KUKA
Published on 10/15/2026 at 18:00, 45 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 10/15/2026 at 18:00, 45 minutes ago Supervisory Board appoints Dr. Marc-Alexander Mahl to the Fresenius Management Board and extends Sara Hennicken’s contract
